It is predicted that in early cancer development, the expression of IDO or HER2 is upregulated in the majority of cancer cells stimulated by various immune molecules, including IFN-γ, IL-10, IL-27, CTLA4, TGF-β, cyclooxygenase-2 and prostaglandin E2, which are regulated by tumor antigen level or tolerogenic tumor microenvironment [33]. The gene discussed is ERBB2; the disease is cancer.